As we approach a new presidency, a new Congress and new leaders in our health agencies, I am concerned that the sense of urgency about COVID-19 appears to have faded. The disease has not been discussed during the election season, even though it is an ongoing and developing public health threat.
A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.
Recent Comments